Tags: US | Tengion | IPO | Priced

Tengion Prices IPO Below Expected Range

Friday, 09 Apr 2010 11:30 AM

Regenerative medicine company Tengion Inc. priced its initial public offering below expectations, raising $30 million, the company's underwriter, Piper Jaffray, said Friday.

Tengion sold 6 million shares to initial investors for $5 apiece, according to Chad Burton, head of Piper's administration group. It had expected them to price from $8 to $10. The company boosted the number of shares sold from 4.4 million.

Current stockholders bought about $17.2 million in stock.

Tengion's technology uses a patient's own cells to create replacement organs and tissues. The company said in a regulatory filing that its auditors have raised doubt about its ability to continue as a going concern.

Tengion intends to use IPO proceeds for fund research, service its debt and maintain its manufacturing facility.

Shares are expected to trade under the symbol "TNGN" on the Nasdaq Friday.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

 
1Like our page
2Share
InvestingAnalysis
Regenerative medicine company Tengion Inc. priced its initial public offering below expectations, raising $30 million, the company's underwriter, Piper Jaffray, said Friday.Tengion sold 6 million shares to initial investors for $5 apiece, according to Chad Burton, head of...
US,Tengion,IPO,Priced
136
2010-30-09
Friday, 09 Apr 2010 11:30 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved